Institutional members access full text with Ovid®

Share this article on:

Is Tailoring Treatment of Rectal Cancer the Only True Benefit of Long-Course Neoadjuvant Chemoradiation? Another View

Bach, Simon P. M.D.

doi: 10.1097/DCR.0b013e318277e8fc
For Debate

University of Birmingham, Edgbaston, Birmingham, United Kingdom

Financial Disclosures: None reported.

Correspondence: Simon P. Bach, M.D., University of Birmingham, School of Cancer Studies, Academic Department of Surgery, Room 28, 4th Floor, Queen Elizabeth Hospital, Edgbaston, Birmingham B15 2TH, United Kingdom. E-mail: s.p.bach@bham.ac.uk

© The ASCRS 2013